These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25903148)

  • 1. Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.
    Zoon CK; Wan W; Graham L; Bear HD
    Int J Mol Sci; 2015 Apr; 16(4):8744-60. PubMed ID: 25903148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.
    Zoon CK; Wan W; Graham L; Bear HD
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
    Gold JE; Osband ME
    Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E; Graham L; Manjili MH; Bear HD
    Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
    Chang ML; Chen YT; Su YC; Kung JT
    J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
    Hinrichs CS; Palmer DC; Rosenberg SA; Restifo NP
    J Immunother; 2005; 28(6):517-24. PubMed ID: 16224268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infusion of ex vivo expanded homologous CD4⁺;CD25⁺; regulatory T cells promotes the susceptibility to tumor in mice].
    Guo T; Luo S; Xu J; Dai J; Liu Z; Gao X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 May; 30(5):466-70. PubMed ID: 24796739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
    Goldfarb RH; Ohashi M; Brunson KW; Kirii Y; Kotera Y; Basse PH; Kitson RP
    Anticancer Res; 1998; 18(3A):1441-6. PubMed ID: 9673353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
    Zeng R; Spolski R; Finkelstein SE; Oh S; Kovanen PE; Hinrichs CS; Pise-Masison CA; Radonovich MF; Brady JN; Restifo NP; Berzofsky JA; Leonard WJ
    J Exp Med; 2005 Jan; 201(1):139-48. PubMed ID: 15630141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.